Recently, Bionova Pharmaceuticals, a cutting-edge innovative drug company, announced the completion of its B+ round of financing. This round was jointly invested by Hanyi Capital, Jinpu Investment, Medfine Capital, Yinglian Health Fund, Rencent International and others.

Prior to this, the company has completed two rounds of financing, with shareholders including Taifu Capital, Hillhouse Capital, OrbiMed Capital, Boyuan Capital, Eli Lilly Asia Fund, etc.

BioNova Pharmaceuticals (Shanghai) Ltd. is a privately held clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative medicines for cancer and other life-threatening diseases with high unmet medical needs. 

Headquartered in Shanghai, BioNova is a fast-growing company of which robust pipeline is built upon internal R&D programs, collaborations with and acquisitions from partners of cutting-edge technology. With a highly capable and experienced team in combination with substantial funding, BioNova is committed to delivering high-quality innovative medicines to patients in China and globally.

“Innovative drug research and development is a long scientific exploration that integrates multiple disciplines and costs a lot of talent. We are fortunate to have received the recognition and support of a group of investors with common ideals and enthusiasm such as Hanyi Capital. We hope to pass The power of capital accelerates the construction of the company's scale and pipeline, and declares new medicines that can solve clinical pain points as soon as possible for the benefit of the people", said Hua Ye, the founder of  Bionova Pharmaceuticals.

Founded in 2014 at the China’s financial hub-Shanghai, Mefund Capital is a young investment fund.

Its businesses have reached to many parts of Mainland China, with offices branches established in Beijing, Shenzhen, Zhejiang, Fujian, Shandong and Jiangxi. The team  focus on investing in healthcare and bio-science industry, seeking to contribute to the assets growth for high-net-worth-individuals, our FOF (Fund of Funds), family offices, enterprise groups as well as listed companies. Our financial services include equity investments(VC/PE), PIPE, FOF, securities investing, M&A and etc.